Harrow (HROW) to Release Quarterly Earnings on Monday

Harrow (NASDAQ:HROW) will likely be announcing its earnings results after the market closes on Monday, March 17th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $58.41 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Harrow Stock Performance

Shares of NASDAQ HROW opened at $23.01 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The firm’s 50-day moving average price is $30.45 and its two-hundred day moving average price is $38.85. Harrow has a 52-week low of $9.30 and a 52-week high of $59.23. The stock has a market capitalization of $819.50 million, a P/E ratio of -24.48 and a beta of 0.69.

Wall Street Analyst Weigh In

Several brokerages have commented on HROW. HC Wainwright began coverage on shares of Harrow in a research note on Thursday, February 6th. They issued a “buy” rating and a $57.00 price target on the stock. B. Riley lowered their price objective on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research note on Wednesday, December 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.